Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers

Simple item page

Simple item page

Full item details

dc.contributor.author
Abe, Kento T.
Hu, Queenie
Mozafarihashjin, Mohammad
Samson, Reuben
Manguiat, Kathy
Robinson, Alyssia
Rathod, Bhavisha
Hardy, W. Rod
Wang, Jenny H.
Iskilova, Mariam
Pasculescu, Adrian
Fazel-Zarandi, Mahya
Li, Angel
Paterson, Aimee
Chao, Gary
Green, Karen
Gilbert, Lois
Barati, Shiva
Haq, Nazrana
Takaoka, Alyson
Takaoka, Julia Garnham
De Launay, Keelia Quinn
Fahim, Christine
Sheikh-Mohamed, Salma
Arita, Yuko
Durocher, Yves
Marcusson, Eric G.
Gommerman, Jennifer L.
Ostrowski, Mario
Colwill, Karen
Straus, Sharon E.
Wood, Heidi
McGeer, Allison J.
Gingras, Anne-Claude
dc.date.accessioned
2024-01-04T14:06:40Z
dc.date.available
2024-01-04T14:06:40Z
dc.date.issued
2021-08
dc.description.abstract - en
Prioritizing Ontario’s long-term care home (LTCH) residents for vaccination against severe acute respiratory syndrome coronavirus 2 has drastically reduced their disease burden; however, recent LTCH outbreaks of variants of concern (VOCs) have raised questions regarding their immune responses. In 198 residents, mRNA vaccine dose 1 elicited partial spike and receptor binding domain antibody responses, while the second elicited a response at least equivalent to convalescent individuals in most residents. Residents administered mRNA-1273 (Moderna) mounted stronger total and neutralizing antibodyresponses than those administered BNT162b2 (Pfizer-BioNTech). Two to four weeks after dose 2, residents (n = 119, median age 88) produced 4.8–6.3-fold fewer neutralizing antibodies than staff (n = 78; median age 47) against wild-type (with D614G) pseudotyped lentivirus, and residents administered BNT162b2 produced 3.89-fold fewer neutralizing antibodies than those who received mRNA-1273. These effects were exacerbated upon serum challenge with pseudotyped VOC spike, with up to 7.94-fold reductions in B.1.351 (Beta) neutralization. Cumulatively, weaker vaccine stimulation, age/comorbidities, and the VOC produced an ~130-fold reduction in apparent neutralization titers in LTCH residents and 37.9% of BNT162b2-vaccinated residents had undetectable neutralizing antibodies to B.1.351. Continued immune response surveillance and additional vaccine doses may be required in this population with known vulnerabilities.
dc.identifier.doi
https://doi.org/10.1101/2021.08.06.21261721
dc.identifier.uri
https://open-science.canada.ca/handle/123456789/1403
dc.language.iso
en
dc.publisher
BMJ
dc.rights - en
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr
Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.uri - en
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en
Health
dc.subject - fr
Santé
dc.subject.en - en
Health
dc.subject.fr - fr
Santé
dc.title - en
Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers
dc.type - en
Submitted manuscript
dc.type - fr
Manuscrit soumis
local.peerreview - en
No
local.peerreview - fr
Non
Download(s)

Original bundle

Now showing 1 - 1 of 1

Thumbnail image

Name: abe-neutralizing-response-sars-cov2-vaccinated-residents.pdf

Size: 5.04 MB

Format: PDF

Download file

Page details

Date modified: